ABT-510

ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD)[1][2].

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

Research Areas >> Inflammation/Immunology

ABT-510 (1, 5, 10, 20, 50 nM; 24 h) induces apoptosis in ID8 cells and (50 nM; 24 h) increases the incidence of apoptosis in the human epithelial cancer cell lines SKOV3, OVCAR3, and CAOV3[1]. Apoptosis Analysis[1] Cell Line: ID8, SKOV3, OVCAR3, and CAOV3 cells Concentration: 1, 5, 10, 20, 50 nM Incubation Time: 24 h Result: Induced ID8 cells apoptosis and increased in apoptosis in the human EOC cell lines SKOV3, OVCAR3, and CAOV3.

ABT-510 (100 mg/kg; i.p.; single daily for 90 days) leads to a significant reduction in tumor size, ascites fluid volume, and secondary lesion dissemination in mice[1]. ABT-510 (100 mg/kg; I.p.; single daily for 90 days) induces cells apoptosis in vivo[1]. ABT-510 (60 mg/kg; osmotic minipumps for s.c.; single daily for 7 days) decreases angiogenesis and inflammation in a murine model of inflammatory bowel disease[2]. Animal Model: TSP-1-Null mice (C57BL/6 background; orthotopic, syngeneic model of epithelial ovarian cancer)[1]. Dosage: 100 mg/kg Administration: Intraperitoneal injection; single daily for 90 days Result: Reduced ovarian tumor growth in wild-type and TSP-1-Null Mice. Significantly reduced the volume of ascites and completely abolished the formation of peritoneal lesions. Reversed ovarian tumor hypervascularization and increased the proportion of mature blood vessels. Animal Model: TSP-1-Null mice (C57BL/6 background; 6-week-old; DSS-induced inflammatory bowel disease murine model)[2]. Dosage: 60 mg/kg Administration: Subcutaneously implanted osmotic minipumps (0.5µL/h); single daily for 7 days Result: Significantly delayed DSS-induced bleeding and improved the overall severity of disease.Significantly diminished inflammation grading and angiogenesis